Effect of glargine combined aspart insulin when stroke happened in type 2 diabetes

Abstract

Abstract: AIM: To explored the combination of glargine and aspart in stoke of diabetes. METHODS: 40 patients were randomly assigned to two groups for insulin therapy, glargine combined aspart group (Agroup); three regular and one NPH( B group) group. Blood glucose was detected 7 times each day. RESULTS: Fasting and post meal blood glucose were more better in A group than B group after 7 days, and less hypoglycemia happened. ( Fasting 7.2±0.8, 9.4±1.9, PK 0.05; post meal, 9.0±1.8, 10.3±2.3,P<0.05, mmol/L). CONCLUSION: Glargine combined aspart w as more effective and has less hypoglycemia in diabetes when stroke happened.

Key words: diabetes, stroke, glargine, aspart

CLC Number:

R587.1

YU Ping, LI Qiang, YANG Chun-xiao, SUN Yu-qian, LIANG Qing-cheng, ZHANG Jin-chao. Effect of glargine combined aspart insulin when stroke happened in type 2 diabetes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(4): 449-451.

References

[1] Monnier L,Lapinsbi H,Coletle C,et al. Contributions of fasting and post prandial pl asma glucose increments to the overall diurnal byperglycemia of type 2 diabetic patients:variations w ith increasing levels of HbA(1c)[J].Diabetes Care,2003,26(3):881-885.
[2] 钱荣立.关于糖尿病的新诊断标准与分型[J].中国糖尿病杂志,2000,8(1):5-6.
[3] Genich JE. Insulin glargi ne:long-acting basal insulin analog for improved metabolic contol[J].Curr Med Opin,2004,20(1):31-37.
[4] Manini R,Forlani G,Moscatielo S,et al. Insulin glarg ne improves glycemic cont rol and healthrel ated quality of life in type 1 diabetes[J]. Nutr Metab Cardiovasc Dis,2007,17(7):493-498.
[5] Bi YF,Zhao LB,li XY,et al. A 2-way cross over,openr labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients[J]. Chin Med J (Engl),2007,120(19):1700-1703.
[6] Petitt DJ,Ospina P,Howard C,et al. Eficacy,safety and lack of immunogenicity of insuli n aspart compared with regular human insulin for women with gestational diabetes mellitus[J]. Diabet Med,2007,24(10):1129-1135.
[7] Gag SK,Gottied PA,Hisatomi ME,et al. Improved glycemic control without an increase in severe hypoglyoemic epi sodes in intensively treated patients with type 1 diabetes receiving morning evening or split dose insulin glargine[J]. Diabetes Res Clin Pact,2004,66(1):49-56.
[8] Triplitt C,Glass L,Miyazaki Y,et al. Comparison of glargi ne insulin versus rosiglitazone ad tion in poorly controlled type 2 diabetic patients on metfomin plus sulfonylurea[J].Diabetes Care,2006,29(11):2371-2377.
[9] Janka HU,Plewe G,Riddle MC,et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes[J].Diabetes Care,2005,28(2):254-259.
[10] Raskin P,Allen E,Hollander P,et al. Initiat ing insulin therapy in type 2 Diabetes:a companison of biphasic and basal insulin analogs[J].Diabetes Care,2005,28(2):260-265.
[11] Braendle M. Cost effecti veness analysis of insulin glargine compared with NPH insulin based on a 10 year simulation of long tem complications with the di abetes mellitus model in patients with type 2 diabetes in Switzerland[J].Di abetologa,2004,47(Suppll):Abs957.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[3]	WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng. Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
[4]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[5]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[6]	QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei. Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713.
[7]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[8]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[9]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[10]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[11]	CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
[12]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[13]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[14]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[15]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.